On July 13, 2022 Heidelberg Pharma and Chiome Bioscience reported the signing of an exclusive, target-specific research and option agreement (Press release, Heidelberg Pharma, JUL 13, 2022, View Source [SID1234633373]). Heidelberg Pharma Research GmbH signed this collaboration, which will combine one of Chiome’s monoclonal antibodies against one specific target with Heidelberg Pharma’s proprietary ATAC platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Chiome will have access to Heidelberg Pharma’s Amanitin toxin-linker platform technology and has an option for an exclusive, target-specific license for global development and commercialization rights to the product candidate resulting from the research collaboration.

Heidelberg Pharma would be eligible to receive an option fee, development- and salesrelated milestone payments of up to 105 million Euro as well as tiered royalties in the midupper single digit range.